These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 25955225)

  • 21. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
    Llach F; Yudd M
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism.
    Park CW; Oh YS; Shin YS; Kim CM; Kim YS; Kim SY; Choi EJ; Chang YS; Bang BK
    Am J Kidney Dis; 1999 Jan; 33(1):73-81. PubMed ID: 9915270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients.
    Fukagawa M; Kitaoka M; Yi H; Fukuda N; Matsumoto T; Ogata E; Kurokawa K
    Nephron; 1994; 68(2):221-8. PubMed ID: 7830860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
    Ong LM; Narayanan P; Goh HK; Manocha AB; Ghazali A; Omar M; Mohamad S; Goh BL; Shah S; Seman MR; Vaithilingam I; Ghazalli R; Rahmat K; Shaariah W; Ching CH;
    Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.
    Oyama Y; Kazama JJ; Omori K; Higuchi N; Kameda S; Yamamoto S; Ito Y; Maruyama H; Narita I; Gejyo F
    Clin Exp Nephrol; 2005 Jun; 9(2):142-7. PubMed ID: 15980949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcium-mediated parathyroid hormone suppression to assess progression of secondary hyperparathyroidism during treatment among incident dialysis patients.
    Rodriguez M; Ureña-Torres P; Pétavy F; Cooper K; Farouk M; Goodman WG
    J Clin Endocrinol Metab; 2013 Feb; 98(2):618-25. PubMed ID: 23365129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of clinical-ultrasonographic feature model to predict the severity of secondary hyperparathyroidism.
    Zhang X; Xu W; Huang T; Huang J; Zhang C; Zhang Y; Xie X; Xu M
    Ren Fail; 2022 Dec; 44(1):146-154. PubMed ID: 35164637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased blood lead levels after calcitriol treatment in hemodialysis patients with secondary hyperparathyroidism.
    Lu KC; Wu CC; Ma WY; Chen CC; Wu HC; Chu P
    Bone; 2011 Dec; 49(6):1306-10. PubMed ID: 21985997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination Therapy of Denosumab and Calcitriol for a Renal Transplant Recipient with Severe Bone Loss due to Therapy-Resistant Hyperparathyroidism.
    Wada Y; Iyoda M; Iseri K; Arai-Nunota N; Saito T; Hamada T; Tachibana S; Ikeda M; Shibata T
    Tohoku J Exp Med; 2016 Mar; 238(3):205-12. PubMed ID: 26947314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of weekly percutaneous maxacalcitol injection therapy in patients with secondary hyperparathyroidism.
    Saito A; Matsumoto Y; Oyama Y; Asaka M; Yokoyama H
    Ther Apher Dial; 2010 Feb; 14(1):98-103. PubMed ID: 20438525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcitriol pulse therapy and histology of parathyroid glands in hemodialysis patients.
    Lomonte C; Martino R; Selvaggiolo M; Bona RM; Cazzato F; Milano R; Chiarulli G; Basile C
    J Nephrol; 2003; 16(5):716-20. PubMed ID: 14733419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Total parathyroidectomy in treatment of Sagliker syndrome in 10 cases of hemodialysing patients with secondary hyperparathyroidism].
    Zhang L; Yao L; Hua Z; Bian WJ; Li WG
    Zhonghua Nei Ke Za Zhi; 2011 Jul; 50(7):562-7. PubMed ID: 22041265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parathyroidectomy in patients with chronic kidney disease: Impacts of different techniques on the biochemical and clinical evolution of secondary hyperparathyroidism.
    Albuquerque RFC; Carbonara CEM; Martin RCT; Dos Reis LM; do Nascimento CP; Arap SS; Moysés RMA; Jorgetti V; Montenegro FLM; de Oliveira RB
    Surgery; 2018 Feb; 163(2):381-387. PubMed ID: 29146232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
    Lu KC; Tseng CF; Wu CC; Yeung LK; Chen JS; Chao TY; Janckila AJ; Yam LT; Chu P
    Blood Purif; 2006; 24(5-6):423-30. PubMed ID: 16888370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin D receptor genotype influences parathyroid hormone and calcitriol levels in predialysis patients.
    Marco MP; Martínez I; Amoedo ML; Borràs M; Saracho R; Almirall J; Fibla J; Fernández E
    Kidney Int; 1999 Oct; 56(4):1349-53. PubMed ID: 10504487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.